Location History:
- Phoenix, AZ (US) (2014 - 2015)
- Chandler, AZ (US) (2010 - 2019)
Company Filing History:
6 out of 119 
3 out of 973 Years Active: 2010-2019
Title: The Innovative Contributions of Haiyong Han
Introduction
Haiyong Han is a notable inventor based in Chandler, AZ, who has made significant strides in the field of cancer treatment through his innovative patents. With a total of 6 patents to his name, his work primarily focuses on the development of methods and kits designed to predict therapeutic outcomes in patients undergoing treatment with Bruton’s Tyrosine Kinase (BTK) inhibitors.
Latest Patents
Among his latest patents, Han has developed methods and kits that assess the expression of the DPC4 (SMAD4) gene to identify pancreatic cancer patients who are likely or unlikely to respond to BTK inhibitor treatments. His innovations include therapeutic targets for cancers that feature the inactivation of the DPC4 gene or protein. Furthermore, Han's patents describe methods for screening new therapeutic agents using these targets. One of the pharmaceutical compositions he has worked on comprises BTK inhibitors, such as PCI-32765 or its derivatives, which serve as potential treatments for cancer. The associated kits facilitate the performance of these groundbreaking methods.
Career Highlights
Haiyong Han has contributed his expertise to reputable institutions such as the Translational Genomics Research Institute and the Arizona Board of Regents on behalf of the University of Arizona. His work has been vital in advancing cancer therapeutics and improving patient outcomes.
Collaborations
Throughout his career, Han has collaborated with esteemed colleagues, including Daniel D. Von Hoff and Caroline Huynh Diep, both of whom are recognized figures in the field of cancer research. These collaborations have enhanced the impact of his innovations and led to further advancements in cancer treatment strategies.
Conclusion
Haiyong Han continues to be a pivotal figure in the realm of therapeutic innovations, particularly in the treatment of cancer through BTK inhibitors. His patents reflect a commitment to enhancing patient care and advancing scientific understanding, making him a noteworthy inventor in modern medical research.